Amanta Healthcare Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Amanta Healthcare Ltd filed with BSE on 08 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Amanta Healthcare reported Q1 FY27 revenue of INR69 crores, up roughly 5% year-on-year, with EBITDA of about INR15 crores and an EBITDA margin of approximately 22%. Management attributed cost pressure to a polymer price spike linked to the Middle East crisis and to overheads absorbed ahead of the delayed SteriPort Line 3 commissioning. The company detailed capex, timelines and expected margin impact from the SteriPort expansion, the SVP facility, and the newly commissioned captive solar power plant.
Numbers mentioned
Revenue: INR69 crores (Q1 FY27)
p. 3
“During the quarter, we reported revenue of INR69 crores, up by roughly 5% year-on-year, while maintaining a healthy EBITDA margin of approximately 22%.”
Bhavesh Patel, page 3 of the filed PDF · View the filing
EBITDA: about INR15 crores (Q1 FY27)
p. 4
“We reported EBITDA of about INR15 crores with EBITDA margin remaining at about 22%.”
Paras Mehta, page 4 of the filed PDF · View the filing
SteriPort revenue contribution: around 44% of revenue
p. 3
“Our SteriPort platform, which now contributes around 44% of our revenue, continues to witness strong customer acceptance.”
Bhavesh Patel, page 3 of the filed PDF · View the filing
SVP business contribution to revenue: around 20% (FY26)
p. 4
“The SVP business contributed around 20% of FY26 revenue, and we expect the new facility to commence operations during Q4 FY27, further expanding our presence in high-margin export market.”
Bhavesh Patel, page 4 of the filed PDF · View the filing
Captive solar power project size: 10.8 megawatt
p. 4
“On the cost optimization front, our 10.8 megawatt captive solar power project has already been commissioned since June '26.”
Bhavesh Patel, page 4 of the filed PDF · View the filing
Incremental depreciation from new line: about INR4.5 crores annually (FY27)
p. 5
“So, estimated depreciation will be about INR4.5 crores from the new line.”
Bhavesh Patel, page 5 of the filed PDF · View the filing
Total incremental depreciation increase: about INR6 crores annually (FY27 vs FY26)
p. 5
“So, total depreciation for the company will be INR6 crores additional compared to FY26.”
Paras Mehta, page 5 of the filed PDF · View the filing
Polymer price selling price increase: INR1.50
p. 12
“So, the selling price was increased by INR1.50.”
Bhavesh Patel, page 12 of the filed PDF · View the filing
Polymer price increase impact: roughly INR2.25
p. 12
“And the impact of the polymer increase was roughly INR2.25.”
Bhavesh Patel, page 12 of the filed PDF · View the filing
Solar captive savings: roughly INR75 lakh a month
p. 13
“So, this solar captive was a no-brainer because it is saving roughly INR75 lakh a month.”
Bhavesh Patel, page 13 of the filed PDF · View the filing
Working capital days: 141 (FY26)
p. 13
“our networking capital days for FY26 stands at 141 and our debt-to-equity obviously, it has been on a decreasing trend, but still stands at 1.06.”
Urmish Shah, page 13 of the filed PDF · View the filing
SteriPort Line 3 capex: INR90 crores total, INR80 crores spent so far
p. 17
“So, SteriPort Line 3 is expected to have INR90 crores of total capex, out of which almost INR80 crores has been spent so far.”
Paras Mehta, page 17 of the filed PDF · View the filing
SVP capex: INR30 crores total, INR7 crores spent so far
p. 17
“SVP is expected to have about INR30 crores of capex, out of which about INR7 crores has been spent so far and remaining will be spent in coming quarters.”
Paras Mehta, page 17 of the filed PDF · View the filing
Effective tax rate: 26% (FY27/FY28)
p. 18
“26% effective tax rate in books. 26.”
Paras Mehta, page 18 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
SteriPort Line 3 annualized revenue — INR120 crores · within 12 months of commissioning
stated firmly by Bhavesh Patel
p. 5
“So, that is a annualized number. So, the production capacity and the net realization that we envisage are not changing. So, on annualized basis, we should be getting INR120 crores top line.”
Bhavesh Patel, page 5 of the filed PDF · View the filing
SteriPort Line 3 commercial production start — last week of August
stated conditionally by Bhavesh Patel
p. 4
“and we intend to take the commercial production in the last week of August, whenever we reach that stage, we will keep you posted.”
Bhavesh Patel, page 4 of the filed PDF · View the filing
SVP facility commissioning — Q4 FY27
stated firmly by Bhavesh Patel
p. 4
“The SVP business contributed around 20% of FY26 revenue, and we expect the new facility to commence operations during Q4 FY27, further expanding our presence in high-margin export market.”
Bhavesh Patel, page 4 of the filed PDF · View the filing
EBITDA margin expansion from SteriPort/solar — 4% to 5%
stated conditionally by Bhavesh Patel
p. 6
“So, we were targeting 5% expansion with INR9 crores saving. So, 4% to 5% with INR9 crores. So, to be mean fairly accurate.”
Bhavesh Patel, page 6 of the filed PDF · View the filing
Revenue for current fiscal year — roughly INR370 crores · FY27
stated conditionally by Bhavesh Patel
p. 8
“And baseline numbers right now is so, roughly we can in spite of 5 months delay on SteriPort Line 3, we can still close at roughly 370 or so.”
Bhavesh Patel, page 8 of the filed PDF · View the filing
Peak revenue with SteriPort and SVP — Roughly INR425 crores · FY28
stated as an aspiration by Bhavesh Patel
p. 8
“Roughly INR425 crores.”
Bhavesh Patel, page 8 of the filed PDF · View the filing
EBITDA margin at peak utilization — 25%-26% · FY27 and FY28
stated as an aspiration by Bhavesh Patel
p. 9
“Margin about 25%-26%.”
Bhavesh Patel, page 9 of the filed PDF · View the filing
SVP commercialization timing — February to March '27
stated conditionally by Bhavesh Patel
p. 7
“To answer that, it would be in somewhere in March, February to March '27.”
Bhavesh Patel, page 7 of the filed PDF · View the filing
First inhalation product commercialization — mid-September
stated firmly by Bhavesh Patel
p. 8
“We have taken exhibit batches, and I think, one would be commercialized very soon in September, mid-September.”
Bhavesh Patel, page 8 of the filed PDF · View the filing
Debt reduction — INR30 crores-INR35 crores annually
stated conditionally by Bhavesh Patel
p. 13
“But I think the debt overall annually will keep reducing by INR30 crores-INR35 crores.”
Bhavesh Patel, page 13 of the filed PDF · View the filing
EBITDA contribution from SteriPort in current year — INR70 crores · 7 months from September 1st
stated conditionally by Bhavesh Patel
p. 14
“And as we said, we have 7 months of operational time available for this year from September 1st onwards. So, that should give us roughly INR70 crores of EBITDA top line.”
Bhavesh Patel, page 14 of the filed PDF · View the filing
Interest expense — about INR18 crores-INR19 crores · FY28
stated conditionally by Paras Mehta
p. 18
“So, it should be on annualized basis, it should be about INR18 crores-INR19 crores.”
Paras Mehta, page 18 of the filed PDF · View the filing
Interest expense — about INR21 crores · FY27
stated conditionally by Paras Mehta
p. 19
“'27 should be about INR21 crores.”
Paras Mehta, page 19 of the filed PDF · View the filing
Advanced market share of SVP revenue — 60%-70%
stated as an aspiration by Bhavesh Patel
p. 13
“So, going forward, we would have maybe 60%-70% of revenue of SVP coming from advanced markets only.”
Bhavesh Patel, page 13 of the filed PDF · View the filing
F&D and regulatory team size — 8-10 people in F&D, 3-4 in regulatory affairs
stated as an aspiration by Bhavesh Patel
p. 15
“I believe that we would have around 8 people to 10 people only in F&D, and around 3 people to 4 people in regulatory affairs for advanced/semi-advanced market.”
Bhavesh Patel, page 15 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management confirmed the annualized figure holds and would be achieved within 12 months of commissioning.
Answered by Bhavesh Patel
Asked by Avnish Burman: Will the INR110-120 crore peak revenue from SteriPort Line 3 be realized within 12 months of commissioning?
p. 5
“So, that is a annualized number. So, the production capacity and the net realization that we envisage are not changing. So, on annualized basis, we should be getting INR120 crores top line.”
Bhavesh Patel, page 5 of the filed PDF · View the filing
Management clarified SteriPort realization is actually higher, and the LVP figure the analyst cited related to formulation products with a wider spectrum of value.
Answered by Bhavesh Patel
Asked by Avnish Burman: Is SteriPort realization lower than single-port LVP realization as per the DRHP?
p. 6
“Other way round. Other way round.”
Bhavesh Patel, page 6 of the filed PDF · View the filing
Management cited overheads absorbed ahead of SteriPort commissioning (which got delayed) and some polymer price impact from the Middle East crisis.
Answered by Bhavesh Patel
Asked by Nikhil Agarwal: What caused the cost pressures mentioned in the presentation?
p. 7
“So, in this quarter, we are absorbing the overheads without any contribution from SteriPort Line 3 due to delay.”
Bhavesh Patel, page 7 of the filed PDF · View the filing
Management estimated roughly INR425 crores in FY28 at peak utilization across SteriPort and SVP.
Answered by Bhavesh Patel
Asked by Preet Shah: What is the total revenue potential at peak utilization once all capacities are live?
p. 8
“Roughly INR425 crores.”
Bhavesh Patel, page 8 of the filed PDF · View the filing
Management said there was some stress from polymer volatility but expected most of it to be absorbed through price correction within the quarter and the remainder in the following quarter.
Answered by Bhavesh Patel
Asked by Divya Daga: Are we expecting stress in gross profit margin this quarter due to polymer prices?
p. 10
“So, we are hopeful that during the quarter, we should be able to absorb this spike by at least 70% or so, and remaining can be absorbed in the following quarter.”
Bhavesh Patel, page 10 of the filed PDF · View the filing
Management explained the company already has experience in advanced markets from past exports and is now expanding capacity to serve them further.
Answered by Bhavesh Patel
Asked by Urmish Shah: Why enter regulated markets like UK rather than deepen existing markets?
p. 13
“Amanta has been the only company which has exported this this product to Australia and Canada for 3 years.”
Bhavesh Patel, page 13 of the filed PDF · View the filing
Management gave the total planned capex and amount spent to date for each project.
Answered by Paras Mehta
Asked by Deeya Jain: How much capex has been spent on SteriPort Line 3 and SVP?
p. 17
“SVP is expected to have about INR30 crores of capex, out of which about INR7 crores has been spent so far and remaining will be spent in coming quarters.”
Paras Mehta, page 17 of the filed PDF · View the filing
Management confirmed the analyst's estimates of roughly 16-17% for SteriPort and 14-15% for SVP.
Answered by Bhavesh Patel
Asked by Avnish Burman: What is the incremental ROCE on the new SteriPort line and SVP?
p. 18
“Yes. Almost right, couple of percentage here and there. So, it should be around 14%-15%.”
Bhavesh Patel, page 18 of the filed PDF · View the filing
Risks flagged
Polymer price volatility linked to the Middle East crisis
p. 10
“The polymer prices went up by roughly 70% to 80%, but this spike was only for 2 months.”
Bhavesh Patel, page 10 of the filed PDF · View the filing
Delay in SteriPort Line 3 commissioning due to civil construction
p. 3
“While the SteriPort expansion was originally targeted for commissioning during Q1, the operational delays, mainly due to the delay in the civil construction activity, have shifted the commencement to Q2 FY27.”
Bhavesh Patel, page 3 of the filed PDF · View the filing
Business slowdown due to Iran war situation across all segments
p. 4
“Company has delivered a stable financial performance despite operating in an environment which is characterized by inflationary cost pressures as well as business slowdown due to Iran war situation across all segments.”
Paras Mehta, page 4 of the filed PDF · View the filing
Overheads absorbed ahead of commercial production without contribution from new line
p. 7
“So, in this quarter, we are absorbing the overheads without any contribution from SteriPort Line 3 due to delay.”
Bhavesh Patel, page 7 of the filed PDF · View the filing
SVP approval and market penetration process is slow and dependent on regulatory changes
p. 11
“But SVP is a slow process in terms of product approval, market penetration.”
Bhavesh Patel, page 11 of the filed PDF · View the filing
Dependence on FDA inspection timing for SteriPort Line 3 operational start
p. 9
“But this also depends upon when the FDA comes and finally inspects.”
Bhavesh Patel, page 9 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.